设为首页 加入收藏

TOP

Docetaxel Winthrop 80 mg/4 ml concentrate for solution forin
2014-01-16 00:35:05 来源: 作者: 【 】 浏览:406次 评论:0

For doctors

 

What is it and how is it used?

The name of this medicine is Docetaxel Winthrop. Its common name is docetaxel. Docetaxel is a substance derived from the needles of yew trees.
Docetaxel belongs to the group of anti-cancer medicines called taxoids.

Docetaxel Winthrop has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:

What do you have to consider before using it?

You must not be given Docetaxel Winthrop

Take special care with Docetaxel Winthrop

Before each treatment with Docetaxel Winthrop, you will have blood tests to check that you have enough blood cells and sufficient liver function to receive Docetaxel Winthrop. In case of white blood cells disturbances, you may experience associated fever or infections.

You will be asked to take premedication consisting of an oral corticosteroid such as dexamethasone, one day prior to Docetaxel Winthrop administration and to continue for one or two days after it in order to minimise certain undesirable effects which may occur after the infusion of Docetaxel Winthrop in particular allergic reactions and fluid retention (swelling of the hands, feet, legs or weight gain).

During treatment, you may be given other medicines to maintain the number of your blood cells.

Docetaxel Winthrop contains alcohol. Discuss with your doctor if you suffer from alcohol dependency or liver impairment. See also section “Important information about some of the ingredients of Docetaxel Winthrop” below.

Taking other medicines

Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicine, including medicines obtained without a prescription. This is because Docetaxel Winthrop or the other medicine may not work as well as expected and you may be more likely to get a side effect.

Pregnancy

Ask your doctor for advice before being given any medicine.

Docetaxel Winthrop must NOT be administered if you are pregnant unless clearly indicated by your doctor.

You must not become pregnant during treatment with this medicine and must use an effective method of contraception during therapy , because Docetaxel Winthrop may be harmful for the unborn baby. If pregnancy occurs during your treatment, you must immediately inform your doctor.

If you are a man being treated with Docetaxel Winthrop you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility.

Breast-feeding

You must not breast-feed while you are treated with Docetaxel Winthrop.

Driving and using machines

There is no reason why you cannot drive between courses of Docetaxel Winthrop except if you feel dizzy or are unsure of yourself.

Important information about some of the ingredients of Docetaxel Winthrop.

This medicinal product contains 50 vol % ethanol (alcohol), i.e. up to 1.58 g (2 ml) per vial, equivalent to 40 ml of beer or 17 ml wine per vial.
Harmful for those suffering from alcoholism.
To be taken into account if you are pregnant or if you are breast-feeding women, in children and high-risk groups such as patients with liver disease, or epilepsy.

The amount of alcohol in this medicinal product may alter the effects of other medicines.

The amount of alcohol in this medicine may impair your ability to drive or use machines.

How is it used?

Docetaxel Winthrop will be administered to you by a healthcare professional.

Usual dose

The dose will depend on your weight and your general condition. Your doctor will calculate your body surface area in square meters (m²) and will determine the dose you should receive.

Method and route of administration

Docetaxel Winthrop will be given by infusion into one of your veins (intravenous use). The infusion will last approximately one hour during which you will be in the hospital.

Frequency of administration

You should usually receive your infusion once every 3 weeks.

Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to Docetaxel Winthrop. In particular, please inform your doctor in case of diarrhoea, sores in the mouth, feeling of numbness or pins and needles, fever and give her/him results of your blood tests. Such information will allow her/him to decide whether a dose reduction is needed. If you have any further questions on the use of this medicine, ask your doctor, or hospital pharmacist.

What are possible side effects?

Like all medicines, Docetaxel Winthrop can cause side effects, although not everybody gets them.

Your doctor will discuss these with you and will explain the potential risks and benefits of your treatment.

The frequency of possible side effects listed below is defined using the following convention: very common (affects more than 1 user in 10); common (affects 1 to 10 users in 100); uncommon (affects 1 to 10 users in 1,000); rare (affects 1 to 10 users in 10,000); very rare (affects less than 1 user in 10,000); not known (frequency cannot be estimated from the available data).

The most commonly reported adverse reactions of Docetaxel Winthrop alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.

The severity of adverse events of Docetaxel Winthrop may be increased when Docetaxel Winthrop is given in combination with other chemotherapeutic agents.

During the infusion at the hospital the following allergic reactions (experienced in more than 1 person in 10) may occur:

The hospital staff will monitor your condition closely during treatment. Tell them immediately if you notice any of these effects.

Between infusions of Docetaxel Winthrop the following may occur, and the frequency may vary with the combinations of medicines that are received

Very common (affects more than 1 user in 10):

Common (affects 1 to 10 users in 100):

Uncommon (affects 1 to 10 users in 1,000):

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or hospital pharmacist.

How should it be stored?

Keep out of the reach and sight of children.

Do not use Docetaxel Winthrop after the expiry date which is stated on outer carton and on the label of the vial after EXP. The expiry date refers to the last day of that month.

Do not store above 25°C.
Store in the original package in order to protect from light.

Use the vial immediately after its opening. If not used immediately, in-use storage times and conditions are the responsibility of the user.

From a microbiological point of view, reconstitution/dilution must take place in controlled and aseptic conditions.

Use immediately the medicine once added into the infusion bag . If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 6 hours below 25°C including the one hour infusion.

Physical and chemical in-use stability of the infusion solution prepared as recommended has been demonstrated in non-PVC bags up to 48 hours when stored between 2 to 8°C.

Docetaxel infusion solution is supersaturated, therefore may cristallize over time. If crystals appear, the solution must no longer be used and shall be discarded.

Dispose any unused product or waste material in accordance with local requirements.

↑ back to table of contents ↑

For doctors

What is it?

Docetaxel Winthrop is a medicine that contains the active substance docetaxel. It is available in two forms:

as two vials one containing a concentrated solution and the other containing a solvent, whose contents are mixed together before being made up into a solution for infusion drip into a vein

a single vial containing a concentrate that is ready to make up into a solution for infusion.

What is it used for?

Docetaxel Winthrop is used to treat the following types of cancer:

breast cancer. Docetaxel Winthrop can be used on its own after other treatments have failed. It can also be used with other anticancer medicines doxorubicin, cyclophosphamide, trastuzumab or capecitabine in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated

non-small-cell lung cancer. Docetaxel Winthrop can be used on its own after other treatments have failed. It can also be used with cisplatin another anticancer medicine in patients who have not yet received any treatment for their cancer

prostate cancer, when the cancer does not respond to hormonal treatment. Docetaxel Winthrop is used with prednisone or prednisolone anti-inflammatory medicines

gastric adenocarcinoma a type of stomach cancer in patients who have not yet received any treatment for their cancer. Docetaxel Winthrop is used with cisplatin and 5-fluorouracil other anticancer medicines

head and neck cancer in patients whose cancer is advanced has started to spread. Docetaxel Winthrop is used with cisplatin and 5-fluorouracil.

For full details, see the summary of product characteristics (also part of the EPAR).

The medicine can only be obtained with a prescription.

How is it used?

Docetaxel Winthrop should be used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.

Docetaxel Winthrop is given as a one-hour infusion every three weeks. The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated. Docetaxel Winthrop is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm ). Dexamethasone (an anti-inflammatory medicine) should also be given to the patient, starting on the day before the Docetaxel Winthrop infusion. For more information, see the summary of product characteristics.

How does it work?

The active substance in Docetaxel Winthrop, docetaxel, belongs to the group of anticancer medicines known as the taxanes. Docetaxel blocks the ability of cells to destroy the internal ‘skeleton’ that allows them to divide and multiply. With the skeleton still in place, the cells cannot divide and they eventually die. Docetaxel also affects non cancer cells such as blood cells, which can cause side effects.

How has it been studied?

Docetaxel Winthrop has been studied in over 4,000 breast-cancer patients, around 2,000 small-cell-lung-cancer patients, 1,006 prostate-cancer patients, 457 gastric-adenocarcinoma patients and 897 head- and neck-cancer patients. In most of these studies, Docetaxel Winthrop was combined with other anticancer treatments and compared either with combinations of different treatments or with the same treatments but without Docetaxel Winthrop. The main measures of effectiveness were the number of patients whose cancer responded to treatment, how long the patients lived without their disease getting worse and how long the patients survived.

What benefits has it shown during the studies?

Adding Docetaxel Winthrop to other anticancer treatments produced increases in the number of patients whose cancer responded to treatment, how long the patients lived without their disease getting worse and how long the patients survived, in all five types of cancer. When used on its own, Docetaxel Winthrop was at least as effective as and sometimes more effective than the comparator medicines in breast cancer, and more effective than best supportive care (any medicines or techniques to help patients, but not other anticancer medicines) in lung cancer.

What is the risk associated?

The most common side effects with Docetaxel Winthrop (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils), anaemia (low red blood cell counts), thrombocytopenia (low blood platelet counts), febrile neutropenia (neutropenia with fever), peripheral sensory neuropathy (nerve damage in the hands and feet), peripheral motor neuropathy (damage to the nerves causing difficulty co-ordinating movements), dysgeusia (taste disturbances), dyspnoea (difficulty breathing), stomatitis (inflammation of the lining of the mouth), diarrhoea, nausea (feeling sick), vomiting, alopecia (hair loss), skin reactions, nail disorders, myalgia (muscle pain), loss of appetite, infections, fluid retention, asthenia (weakness), pain and hypersensitivity (allergic reactions). These side effects may be more severe when Docetaxel Winthrop is used with other anticancer medicines. For the full list of all side effects reported with Docetaxel Winthrop, see the package leaflet.

Docetaxel Winthrop should not be used in people who may be hypersensitive (allergic) to docetaxel or any of the other ingredients. Docetaxel Winthrop must not be used in patients who have a neutrophil count of less than 1,500 cells/mm or who have severe problems with their liver.

Why has it been approved?

The CHMP decided that Docetaxel Winthrop’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union for Docetaxel Winthrop to Aventis Pharma S.A. on 20 April 2007. This authorisation was based on the authorisation granted to Taxotere in 1995 (‘informed consent’). The marketing authorisation is valid for five years, after which it can be renewed.

For more information about treatment with Docetaxel Winthrop, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This summary was last updated in 06-2010.

↑ back to table of contents ↑
 

Name

 

Docetaxel Winthrop 80 mg/4 ml concentrate for solution for
infusion

 

Composition

 

Each ml of concentrate contains 20 mg docetaxel as trihydrate.

One vial of 4 ml of concentrate contains 80 mg of docetaxel.

Excipients:
Each vial of concentrate contains 2 ml of ethanol anhydrous (1.58 g).

For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Concentrate for solution for infusion (sterile concentrate).

The concentrate is a pale yellow to brownish-yellow solution.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Docetaxel Teva 80 mg concentrat.. 下一篇Docetaxel Winthrop 20 mg/0.5 ml..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位